title: Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol.
abstract: BACKGROUND
  Although propranolol has become the first-line therapy for infantile haemangiomas (IHs), no study has yet investigated factors associated with the risk of relapse in children with IH treated with propranolol after cessation of treatment.
  
  
  OBJECTIVE
  To compare factors associated with the risk of relapse in children with IH treated with oral propranolol.
  
  
  METHODS
  We conducted a single-centre retrospective observational study. All files and photographs of patients with IH aged 5 months or less at the time of treatment initiation, and who were seen between 1 June 2008 and 31 December 2011 at the National Reference Center for rare skin diseases of Bordeaux, were retrospectively reviewed.
  
  
  RESULTS
  In total 158 children were included, of whom 118 had not relapsed and 40 had relapsed. Fifty-two patients were boys and 106 were girls (male : female ratio 1 : 2), and 19 had a segmental IH (12%). When conducting multivariate analysis, only IHs with a deep component and those with segmental distribution were independently associated with relapse.
  
  
  CONCLUSIONS
  Our study shows that segmental IHs, as well as haemangiomas with a deeper component, are more at risk of relapse and should thus indicate closer follow-up after treatment interruption, and/or longer treatment.
authors.affiliation: Department of Dermatology and Pediatric Dermatology, National Centre for Rare Skin Disorders, Pellegrin Children's Hospital, Bordeaux, France.
authors.forename: C K
authors.initials: CK
authors.lastname: Ahogo
authors.forename: K
authors.initials: K
authors.lastname: Ezzedine
authors.forename: S
authors.initials: S
authors.lastname: Prey
authors.forename: V
authors.initials: V
authors.lastname: Colona
authors.forename: A
authors.initials: A
authors.lastname: Diallo
authors.forename: F
authors.initials: F
authors.lastname: Boralevi
authors.forename: A
authors.initials: A
authors.lastname: Taïeb
authors.forename: C
authors.initials: C
authors.lastname: Léauté-Labrèze
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000209:etiology*; D011433:Propranolol / Q000008:administration & dosage*; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011433:Propranolol